Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8793904 | Ophthalmology | 2018 | 9 Pages |
Abstract
Mutations that are often found in uveal and cutaneous melanoma were identified in this cohort of iris melanomas and iris nevi. Therefore, iris melanomas harbor a molecular profile comparable to both choroidal melanoma and cutaneous melanoma. These findings may offer adjuvant targeted therapies for iris melanoma. There was no prognostic significance of BAP1 expression as seen in choroidal melanoma. Consequently, iris melanoma is a distinct molecular subgroup of UM. Histologic borderline malignant iris nevi can harbor BAP1 mutations and may be designated iris melanocytic tumors of uncertain malignant potential.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Natasha M. MD, Jolanda BS, Hardeep S. MD, PhD, Karen PhD, Ian G. MD, PhD, Paul MD, PhD, Tom BS, Quincy C.C. BS, Hanneke W. MD, PhD, Annelies PhD, Emine MD, PhD, Robert M. MD, PhD,